Patented Lancet Technology Targeted In New Inter Partes Review Petition
ALEXANDRIA, Va. — In a March 20 petition for inter partes review (IPR), a medical diagnostic company focused on diabetes care seeks cancellation of 21 claims of a patent purportedly directed...To view the full article, register now.
Already a subscriber? Click here to view full article